Karim Gariani1, Jean-Christophe Richard2, Benjamin Kressmann3,2, François R Jornayvaz1, Jacques Philippe1, Benjamin A Lipsky3,4, Ilker Uçkay3,2,5. 1. Service of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland. 2. Orthopedic Surgery Service, Geneva, Switzerland. 3. Service of Infectious Diseases, Geneva, Switzerland. 4. Department of Medicine, University of Washington, Seattle, WA; and. 5. Infectiology, Balgrist University Hospital, Zurich, Switzerland.
Abstract
BACKGROUND: The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown. OBJECTIVE: We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot results in similar rates of clinical remission and adverse events (AE). SUMMARY OF BACKGROUND DATA: The optimal duration of systemic antibiotic therapy, after successful debridement, for soft tissue infections of diabetic patients is unknown. Because of the high recurrence risk, overuse is commonplace. METHODS: This was a randomized, controlled, non-inferiority pilot trial of cases of diabetic foot infection (excluding osteomyelitis) with the primary outcome of "clinical remission at 2-months follow-up". RESULTS: Among 66 enrolled episodes (17% females; median age 71 years), we randomized 35 to the 10-day arm and 31 to the 20-day arm. The median duration of the parenteral antibiotic therapy was 1 day, with the remainder given orally. In the intention-to-treat population, we achieved clinical remission in 27 (77%) patients in the 10-day arm compared to 22 (71%) in the 20-days arm ( P = 0.57). There were a similar proportion in each arm of AE (14/35 versus 11/31; P = 0.71), and remission in the per-protocol population (25/32 vs 18/27; P = 0.32). Overall, 8 soft tissue DFIs in the 10-day arm and 5 cases in the 20-day arm recurred as a new osteomyelitis [8/35 (23%) versus 5/31 (16%); P = 0.53]. Overall, the number of recurrences limited to the soft tissues was 4 (6%). By multivariate analysis, rates of remission (intention-to-treat population, hazard ratio 0.6, 95%CI 0.3-1.1; per-protocol population 0.8, 95%CI 0.4-1.5) and AE were not significantly different with a 10-day compared to 20-day course. CONCLUSIONS: In this randomized, controlled pilot trial, post-debridement antibiotic therapy for soft tissue DFI for 10 days gave similar (and non-inferior) rates of remission and AEs to 20 days. A larger confirmatory trial is under way. TRIAL REGISTRATION: ClinicalTrials NCT03615807.
BACKGROUND: The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown. OBJECTIVE: We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot results in similar rates of clinical remission and adverse events (AE). SUMMARY OF BACKGROUND DATA: The optimal duration of systemic antibiotic therapy, after successful debridement, for soft tissue infections of diabetic patients is unknown. Because of the high recurrence risk, overuse is commonplace. METHODS: This was a randomized, controlled, non-inferiority pilot trial of cases of diabetic foot infection (excluding osteomyelitis) with the primary outcome of "clinical remission at 2-months follow-up". RESULTS: Among 66 enrolled episodes (17% females; median age 71 years), we randomized 35 to the 10-day arm and 31 to the 20-day arm. The median duration of the parenteral antibiotic therapy was 1 day, with the remainder given orally. In the intention-to-treat population, we achieved clinical remission in 27 (77%) patients in the 10-day arm compared to 22 (71%) in the 20-days arm ( P = 0.57). There were a similar proportion in each arm of AE (14/35 versus 11/31; P = 0.71), and remission in the per-protocol population (25/32 vs 18/27; P = 0.32). Overall, 8 soft tissue DFIs in the 10-day arm and 5 cases in the 20-day arm recurred as a new osteomyelitis [8/35 (23%) versus 5/31 (16%); P = 0.53]. Overall, the number of recurrences limited to the soft tissues was 4 (6%). By multivariate analysis, rates of remission (intention-to-treat population, hazard ratio 0.6, 95%CI 0.3-1.1; per-protocol population 0.8, 95%CI 0.4-1.5) and AE were not significantly different with a 10-day compared to 20-day course. CONCLUSIONS: In this randomized, controlled pilot trial, post-debridement antibiotic therapy for soft tissue DFI for 10 days gave similar (and non-inferior) rates of remission and AEs to 20 days. A larger confirmatory trial is under way. TRIAL REGISTRATION: ClinicalTrials NCT03615807.
Authors: Dan Lebowitz; Karim Gariani; Benjamin Kressmann; Elodie von Dach; Benedikt Huttner; Placido Bartolone; Nam Lê; Morad Mohamad; Benjamin A Lipsky; Ilker Uçkay Journal: Int J Infect Dis Date: 2017-04-24 Impact factor: 3.623
Authors: Karim Gariani; Dan Lebowitz; Benjamin Kressmann; Elodie von Dach; Parham Sendi; Felix Waibel; Martin Berli; Tanja Huber; Benjamin A Lipsky; Ilker Uçkay Journal: Diabetes Obes Metab Date: 2019-03-12 Impact factor: 6.577
Authors: Benjamin A Lipsky; Anthony R Berendt; Paul B Cornia; James C Pile; Edgar J G Peters; David G Armstrong; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Michael S Pinzur; Eric Senneville Journal: Clin Infect Dis Date: 2012-06 Impact factor: 9.079
Authors: Joseph L Mills; Michael S Conte; David G Armstrong; Frank B Pomposelli; Andres Schanzer; Anton N Sidawy; George Andros Journal: J Vasc Surg Date: 2013-10-12 Impact factor: 4.268
Authors: Ilker Uçkay; Benjamin Kressmann; Sébastien Di Tommaso; Marina Portela; Heba Alwan; Hubert Vuagnat; Sophie Maître; Christophe Paoli; Benjamin A Lipsky Journal: SAGE Open Med Date: 2018-05-13
Authors: Ilker Uçkay; Benjamin Kressmann; Sarah Malacarne; Anna Toumanova; Jaafar Jaafar; Daniel Lew; Benjamin A Lipsky Journal: BMC Infect Dis Date: 2018-08-02 Impact factor: 3.090
Authors: Amanda Thurler Palomo; Ana Paula Maia Pires; Marcelo Fernando Matielo; Rafael de Athayde Soares; Christiano Pecego; Roberto Sacilotto; Alexandre Inacio de Paula; Nair Hosino; Cristiano de Melo Gamba; Cibele Lefreve Fonseca; Daniela K S Paraskevopoulos; Augusto Yamaguti; João Silva de Mendonça; Silvia Figueiredo Costa; Thaís Guimarães Journal: Antibiotics (Basel) Date: 2022-08-19